# BPC

## RESEARCH



## **Credit Corp Group Limited (CCP)**

### **Finance**

HOLD

**CCP** A\$22.40

**TARGET PRICE \$23.75** 

Credit Corp Group Limited (CCP) is an Australian receivables management company which provides debt purchase and debt collection services, primarily focusing on the acquisition of purchased debt ledgers (PDLs) comprised of distressed consumer debt from Australian and New Zealand banks, finance companies, telecommunication companies and utility providers. CCP has expanded into the US.


Number of shares	67.8M
Market Capitalisation (\$M)	1,649.7
Free float (%)	95.7
12-month high/low	\$35.20/\$18.97
Average Daily Turnover (\$m)	5.1
% S&P/ASX200	0.080%
DDM Ranking	340
% All Ordinaries	0.062%
GICS Industry Group	Finance

### **Earnings Summary (AUD)**

Source: FactSet, BPC

Year end June	2022A	2023F	2024F
Revenue (\$M)	411.2	406.9	444.3
Reported NPAT (\$M)	100.7	92.4	102.0
Adjusted NPAT (\$M)	96.2	93.1	102.7
Reported EPS (¢)	148.9	143.7	157.8
Adjusted EPS (¢ - FD)	142.2	137.4	150.0
Adjusted EPS growth (%)	9.5	8.4	8.1
Adjusted P/E (x)	17.1	13.7	12.6
Dividend (¢/sh)	74.0	72.2	78.6
Gross yield (%)	4.3	4.2	4.6
Net yield (%)	3.0	3.0	3.2
ROIC (%)	15.7	11.9	12.0

Source: Barclay Pearce Capital Barclay Pearce Capital contributes all company estimates to Thomson Reuters, FactSet, Nucleus 195, Capital IQ and Smartkarma.



### **2022 Annual Report Release**

On the 2<sup>nd</sup> of August 2022, Credit Corp Group Limited (CCP) released its 2022 Annual Report, with the following highlights:

### **Highlights:**

- Total Revenue of \$411.2m, up 10% from \$374.8m vs PCP;
- Statutory NPAT of \$100.7m;
- Underlying NPAT of \$96.2m, up 9% from \$88.1m vs PCP;
- Reported EPS of 148.9c;
- Adjusted EPS of 142.2c, up 9% from 130.9c vs PCP;
- Dividend of 74.0c, up 3% from 72.0c vs PCP;
- Pre-tax Operating Cash Flow of \$420.6m, up 2% from \$413.5m vs PCP;
- Income Generating Assets of \$835.7m, up 39% from \$602.5m vs PCP;
- Free Cash Flow (\$100m);
- PDL supply in the core AUS/NZ debt buying market did not recover:
- Collections growth was achieved from purchases of the Radio Rentals and Collection House New Zealand books;
  and
- These one-off acquisitions offset run-off arising from reduced regular direct-from-issuer investment since the start of the pandemic.

### **Outlook:**

- Leading indicators do not suggest a significant recovery in AUS/NZ regular direct-from-issuer PDL sale volumes and US resourcing constraints will not be overcome immediately;
- In FY2023 growth in US segment earnings is not expected to offset the impact of run-off in the AUS/NZ debt buying business:
- While FY2023 has started with a solid investment pipeline, regular investment is expected to moderate from the record levels achieved in FY2022; and
- This should release substantial free cash flow, positioning the Company to secure any sizeable one-off purchasing opportunities that may arise in an uncertain economic environment

### **Guidance:**

- Range of \$220-260mn in PDL Acquisitions for FY23
- Range of \$50-60mn in net lending volumes for FY23
- Range of \$90-97mn NPAT for FY23
- Range of 133-143 cents EPS for FY23

## **Earnings changes**

CCP announced FY23 NPAT guidance in the range of \$90-97m, which is 8-15% below market expectations of \$105.8m. Hence, we expect negative earnings revisions of 12% for FY23 and for future periods.

### **Valuation**

We are updating our 12-month target price from \$26.97 to \$23.75 and retaining our HOLD recommendation. The price target is underpinned by our valuation.

## BPC RESEARCH



#### **Disclaimer**

This Research Report has been prepared by Russell Wright ("Mr Wright") in his capacity as an Authorised Representative (AR: 422117) and is issued by Barclay Pearce Capital Management Pty Ltd (BPCM) AFSL 503261.

This Research is intended solely for the information of the particular person to whom it was provided by BPCM and should not be relied upon by any other person. The information in this Research does not purport to be complete nor does it contain all the information which a prospective investor may require. The information contained in this Research is general in nature and does not constitute advice nor a recommendation to deal. This Research does not constitute specific advice and does not take into account financial objectives or situation of an investor. All and any recipients of this Research acknowledge and agree that they must conduct and have conducted their own due diligence investigation and have not relied upon any representations of BPCM, its officers, employees, representatives or associates. BPCM has not independently verified the information contained in this Research. BPCM assumes no responsibility for updating any information, views or opinions contained in this Research or for correcting any error or omission which may become apparent after the Research has been issued. BPCM does not give any warranty as to the accuracy, reliability or completeness of advice or information which is contained in this Research. Except insofar as liability under any statute cannot be excluded, BPCM and its officers, employees, representatives or associates do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this Research or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this Research or any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party. This Research must not be distributed or released in the United States. It may only be provided to persons who are outside the United States and are not, and are not acting for the account or benefit of, "US Persons" in connection with transactions that would be "offshore transactions" (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). Any securities mentioned in the Research have not been and will not be registered under the Securities Act or the securities laws of any state or jurisdiction of the United States, and may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws in the United States or to, or for the account or benefit of, a US Person. This Research does not, and is not intended to, constitute an offer or invitation in the United States, or in any other place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation. If you are not the intended recipient of this Research, please notify BPCM immediately and destroy all copies of this Research, whether held in electronic or printed form or otherwise.

### **Disclosure of Interest**

The Company, its officers, employees, representatives and associates within the meaning of Chapter 7 of the Corporations Act may receive commissions and management fees from transactions involving securities referred to in this Research (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this Research. The Company does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

### **Analyst Certification**

The research analyst(s) identified above individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report. BPCM provides research services to its client. Mr Wright is General Manager of Research and has over thirty (30) years' experience in the financial services industry, particularly in financial analysis and research report writing. Mr Wright joined the BPCM team in 2021 where he has been involved in the research and publication of reports. Prior to this Mr Wright worked at a number of entities where he held Director/Head of Research and General Manager of Research positions. Mr Wright holds a Bachelor of Mathematics (Honours) from Edinburgh University and has completed the SDIA Accreditation Program (RG146) through DeakinPrime.

#### **Conflicts of Interest**

BPCM does have material interests in the financial product discussed in this Research Report and it will receive benefits in relation to the publication of this Research Report. BPCM manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.

### **Meanings of Barclay Pearce Capital Stock Ratings**

**Buy** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of 15% or more within a 12-month period.

**Hold** – Describes stocks that are neither a buy nor underperform.

**Underperform** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of less than minus 10% within a 12-month period.

**Speculative Buy** – Describes stocks we research with a positive bias, whose company fundamentals and/or financials are being covered, but for which there is insufficient information for BPCM to assign a Buy or Underperform rating.

### **Russell Wright**

## BPC RESEARCH



### **Valuation Methodology**

BPCM's methodology for assigning stock and credit ratings may include the following: market capitalisation, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of peer comparisons, market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of parts, net asset value, discounted dividend model (DDM), franking credits and return on equity (ROE) over the next 12 months.

### **Barclay Pearce Capital Recommendation Proportions**

Buy	37.9%	0.0% of stocks with recommendations are Barclay Pearce clients)
Hold	22.8%	0.0% of stocks with recommendations are Barclay Pearce clients)
Underperform	39.4%	0.0% of stocks with recommendations are Barclay Pearce clients)